Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19692955 | 0.85 | ALDH1A1 (0.54) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL19692956 | 0.85 | ALDH1A1 (0.54) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL29650225 | 0.85 | ALDH1A1 (0.54) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL4430970 | 0.81 | ALDH1A1 (0.53) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL29847319 | 0.80 | ALDH1A1 (0.51) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL5362466 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL29653749 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL9774749 | 0.79 | ALDH1A1 (0.50) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL3738269 | 0.77 | ALDH1A1 (0.47) | ALDH1A1GLATDP1TP53TSHR | |
| SCHEMBL6371705 | 0.75 | ALDH1A1 (0.54) | ALDH1A1GLATDP1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227914-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150183723-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2015-07-02 | — | — | US | disclosed |
| US-8980950-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140057980-A1 | CALCILYTIC COMPOUNDS | GlaxoSmithKline, LLC (US) | 2014-02-27 | — | — | US | disclosed |
| US-8586631-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130158114-A1 | Calcilytic Compounds | GlaxoSmithKline, LLC (US) | 2013-06-20 | — | — | US | disclosed |
| US-8399517-B2 | Calcilytic compounds | GlaxoSmithKline, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110054021-A1 | Calcilytic Compounds | GLAXOSMITHKLINE LLC | 2011-03-03 | — | — | US | disclosed |
| US-7829594-B2 | calcium receptor antagonists such as 3-{3,4-Difluoro-5-[(R)-2-hydroxy-3-(2-indan-2-yl-1,1-dimethyl-ethylamino)-propoxyl]-phenyl}-propionic acid, used to increase serum parathyroid hormone levels in mammals | GlaxoSmithKline, LLC (US) | 2010-11-09 | — | — | US | disclosed |
| US-20090163589-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM. CORP. | 2009-06-25 | — | — | US | disclosed |
| US-7514473-B2 | Calcilytic compounds | SMITHKLINE BEECHAM, CORP. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20060058391-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1569892-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004047751-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163589-A1 | Calcilytic Compounds | SOST, CALCB, CALCR | ALDH1A1 4747/4885GLA 240/4885TDP1 3662/4885 |
| US-20130158114-A1 | Calcilytic Compounds | SOST, CALCB, CALCR | ALDH1A1 4747/4885GLA 240/4885TDP1 3662/4885 |
| US-20060058391-A1 | Calcilytic compounds | SOST, CALCB, CALCR | ALDH1A1 4747/4885GLA 240/4885TDP1 3662/4885 |
| US-20110054021-A1 | Calcilytic Compounds | SOST, CALCB, CALCR | ALDH1A1 4747/4885GLA 240/4885TDP1 3662/4885 |
| US-20150183723-A1 | Calcilytic Compounds | SOST, CALCB, CALCR | ALDH1A1 4747/4885GLA 240/4885TDP1 3662/4885 |
| US-20140057980-A1 | CALCILYTIC COMPOUNDS | SOST, CALCB, CALCR | ALDH1A1 4747/4885GLA 240/4885TDP1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.